# US 2023/0056763 A1 · Methods of targeted sequencing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0056763 A1
- Document ID: US20230056763A1
- Status: Published application
- Kind: A1
- Application number: 17/758,656
- Filed: 2021-01-15
- Published: 2023-02-23
- Earliest claimed: 2020-01-17
- Assignees: Jumpcode Genomics, Inc.
- Applicants: Jumpcode Genomics, Inc.
- Inventors: Keith BROWN
- Web page: https://patentgrep.com/patent/US20230056763A1

## CPC

- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12N 9/1241: {Nucleotidyltransferases (2.7.7)}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12Q 1/6853: using modified primers or templates
- C12Q 1/6869: Methods for sequencing
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are methods and compositions for creating a sequencing library comprising a target nucleic acid. Methods herein can comprise: contacting a nucleic acid sample to a first population of primers, a polymerase, dNTPs, and labeled ddNTPs; performing an extension reaction thereby creating an labeled extension product; contacting the extension product to a second population of primers to create a double stranded extension product comprising the target nucleic acid; contacting the double stranded extension product to a target specific enzyme under conditions allowing cleavage of at least a subset of the double stranded extension product thereby creating a cleaved target nucleic acid; and isolating the cleaved target nucleic acid.

## Claims

### Claim 1

A method of creating a sequencing library comprising a target nucleic acid, the method comprising:
(a) contacting a nucleic acid sample to a first population of primers, a polymerase, dNTPs, and labeled ddNTPs;
(b) performing an extension reaction thereby creating an labeled extension product;
(c) contacting the extension product to a second population of primers to create a double stranded extension product comprising the target nucleic acid;
(d) contacting the double stranded extension product to a target specific enzyme under conditions allowing cleavage of at least a subset of the double stranded extension product thereby creating a cleaved target nucleic acid; and
(e) isolating the cleaved target nucleic acid.

### Claim 2 (depends on 1)

The method of claim 1, wherein the nucleic acid sample is denatured.

### Claim 3 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the first or second population of primers comprise random primers.

### Claim 4 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the first or second population of primers comprise a barcode.

### Claim 5 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the first or second population of primers comprise oligo-dT primers.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1 to 5, wherein the labeled ddNTPs comprise biotin.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1 to 6, wherein the labeled extension product is isolated on a bead.

### Claim 8 (depends on 7)

The method of claim 7, wherein the bead is a streptavidin bead.

### Claim 9 (depends on 7)

The method of claim 7, wherein the bead is a magnetic bead.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1 to 6, wherein the labeled extension product is isolated on a polypropylene, or a polycarbonate surface.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1 to 10, wherein the target specific enzyme is complexed with a target specific guide RNA.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1 to 11, wherein the target specific enzyme is a CRISPR enzyme.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1 to 12, wherein the target specific enzyme is a Cas nuclease.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1 to 13, wherein the target specific enzyme is a Cas9 nuclease.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1 to 10, wherein the target specific enzyme is a nuclease.

### Claim 16 (depends on 15)

The method of claim 15, wherein the nuclease is a restriction endonuclease.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1 to 16, wherein the target nucleic acid is a deoxyribonucleic acid.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1 to 16, wherein the target nucleic acid is a ribonucleic acid.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1 to 18, wherein the polymerase is a DNA polymerase, an RNA polymerase, a reverse transcriptase, or a combination thereof.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1 to 19, wherein the target nucleic acid comprises a viral nucleic acid, a bacterial nucleic acid, a pathogen nucleic acid, a single nucleotide polymorphism, a disease associated gene, a cancer associated gene, a human leukocyte antigen gene, or a combination thereof.

### Claim 21 (depends on 20)

The method of claim 20, wherein the virus is an influenza virus, a coronavirus, a rhinovirus, a herpesvirus, or a human immunodeficiency virus.

### Claim 22 (depends on 21)

The method of claim 21, wherein the coronavirus is a COVID-19 virus.
